Follicular Lymphoma New Indication: Zanubrutinib and Obinutuzumab for R/R Follicular Lymphoma Ulas D. Bayraktar, MD 2023-09-23
Chronic Lymphocytic Leukemia New Reference: Obinutuzumab, ibrutinib, and venetoclax for Untreated CLL Ulas D. Bayraktar, MD 2023-09-23
Diffuse Large B Cell Lymphoma New Drug: Glofitamab for Large B Cell Lymphoma Ulas D. Bayraktar, MD 2023-09-23
Diffuse Large B Cell Lymphoma New Drug: Glofitamab in Large B-Cell Lymphoma Ulas D. Bayraktar, MD 2023-08-20
Diffuse Large B Cell Lymphoma New Protocol: Rituximab, Lenalidomide, and Ibrutinib in DLBCL Ulas D. Bayraktar, MD 2023-06-14
Non-Hodgkin Lymphoma Primary Mediastinal Large B-cell Lymphoma New Reference: Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma Ulas D. Bayraktar, MD 2023-06-07
Diffuse Large B Cell Lymphoma Non-Hodgkin Lymphoma New Drug: Glofitamab-gxbm for selected relapsed or refractory large B-cell lymphomas Ulas D. Bayraktar, MD 2023-06-07
Chronic Lymphocytic Leukemia New Reference: Ibrutinib and Rituximab for CLL Ulas D. Bayraktar, MD 2023-05-20
